What a compounding exemption actually exempts

Three sections, and only three

The compounding provision of the federal drug law does one thing. It switches off three named sections of that law for a preparation that meets its terms.

Read as the statute prints it, the sentence begins by naming them and then immediately makes them conditional. Three sections of the Act "shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order."

The three are the manufacturing-practice provision, the labeling provision that requires adequate directions for use, and the section that requires an approved application before a new drug may be marketed. The agency describes them in the same order on its own page about compounding law.

Everything else in the Act still applies. The exemption is a carve-out from three requirements, not a general exit from federal drug regulation, and a page that treats it as the latter is describing something the statute does not say.

The word "if" is doing most of the work

The exemption is not a status a pharmacy holds. It attaches to a particular preparation, and only while that preparation satisfies the section.

Three things have to be true at once. The drug product is compounded for an identified individual patient. There is a valid prescription order for that person, or a notation on the order, approved by the prescribing practitioner, that a compounded product is necessary for that patient. And the compounding is done by a licensed pharmacist in a state licensed pharmacy or a federal facility, or by a licensed physician.

The statute allows a limited exception to the sequence. A pharmacist or physician may compound in limited quantities before a prescription arrives. That is permitted only on the basis of a history of receiving valid orders for that product, within an established relationship with the patient or the prescriber.

Note where the state appears in a federal sentence. The federal exemption is conditioned on a state license, which is why the two layers of oversight are not alternatives.

What the starting material has to clear

The conditions continue past the prescription and into the powder. A bulk drug substance used in compounding has to pass a three-way test, and that test is covered in detail elsewhere on this site.

Two further conditions on the same substance get much less attention and are easier to check. The substance must be manufactured by an establishment registered with the agency. The statute says so in words that reach abroad, naming an establishment registered under the establishment registration section, "including a foreign establishment" registered under its foreign counterpart.

And each bulk drug substance must be "accompanied by valid certificates of analysis." That duty runs to the compounder receiving the material, not to the person receiving the vial. It is worth knowing which certificate a seller is showing you.

Ingredients that are not bulk drug substances have their own condition. They have to comply with the standards of an applicable pharmacopeial or formulary monograph where one exists.

Two lists that say no

The statute also names two published lists, and both are prohibitions rather than permissions.

The first covers drug products "withdrawn or removed from the market" because they or their components "have been found to be unsafe or not effective." That list exists as a regulation. Its own opening sentence limits its effect to the compounding exemptions in both compounding sections of the Act.

The second covers products the agency has identified as presenting "demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product."

Neither list is a judgment about a molecule in the abstract. Both are answers to a narrower question: may this be compounded under the exemption. Nothing on this site places any compound on or off either one.

The copy rule, and the clause that softens it

One condition is aimed squarely at compounding that starts to look like manufacturing. A compounder may not "compound regularly or in inordinate amounts" any drug products that are "essentially copies of a commercially available drug product."

Then the statute defines the phrase, and the definition is where the practical answer lives. A product is not essentially a copy where a change was made for an identified individual patient. That change has to produce, for that patient, a significant difference from the comparable commercially available product.

Read the qualifiers. The change has to be for an identified patient, it has to produce a significant difference for that patient, and the significance is "as determined by the prescribing practitioner."

That is a clinical judgment recorded about one person. It is not a formulation feature a website can claim on behalf of everyone who orders.

The word "compounding" has its own limit

The section ends with a definition that quietly narrows everything before it.

For the purposes of that section, compounding "does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product's manufacturer."

So preparing an approved product the way its own approved labeling tells you to is not compounding at all under this section. It never needed the exemption, because nothing was switched off.

The section also states two carve-outs of its own. It does not apply to compounded positron emission tomography drugs, or to radiopharmaceuticals.

What a reader can do with this

The useful move is to stop asking whether a pharmacy is allowed to compound, and start asking what the answer depends on.

A preparation sits inside the exemption because of facts about that preparation. A named patient and a valid order. A licensed compounder working in a licensed pharmacy. A qualifying substance from a registered maker, with a certificate of analysis behind it. And a product that is not a routine copy of something already sold.

None of those facts is visible from a product photograph. Several of them become checkable the moment a provider names the pharmacy, which is why this site scores that disclosure rather than treating it as a detail.

And the ceiling stays where it was. The agency states that compounded drugs are not FDA-approved, and that it does not review their safety, effectiveness or quality before they are marketed. Meeting every condition in the section does not change that sentence.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 United States Code section 353a, Pharmacy compounding, text as published with the currency line "Text contains those laws in effect on September 5, 2026" — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
2. Human Drug Compounding Laws, describing the conditions under which compounded human drug products are exempt from approval, current good manufacturing practice and adequate-directions labeling — U.S. Food and Drug Administration, December 2024
3. Title 21 Code of Federal Regulations section 216.24, Drug products withdrawn or removed from the market for reasons of safety or effectiveness — Electronic Code of Federal Regulations, Office of the Federal Register, January 2019
4. Title 21 Code of Federal Regulations section 207.3, Bulk drug substance, recording that the term was previously defined at section 207.3(a)(4) and now means active pharmaceutical ingredient as defined at section 207.1 — Electronic Code of Federal Regulations, Office of the Federal Register, April 2021